Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb66d9373d09efad73c142762f6dfb00 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-002 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
filingDate |
2008-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab044f4c88cfc853b46d631a9e6601ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c59d8df22c546c8a72efd1dba0306349 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dc16697ad07bcdee5dd802baedd4b23 |
publicationDate |
2008-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2687683-A1 |
titleOfInvention |
Modified nucleotide sequence encoding glucagon-like peptide-1 (glp-1) |
abstract |
An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1. Recombinant expression vectors, human transfected cells and methods of producing human GLP-1 constitutively are also provided, as are method of producing GLP-1 and insulin in a glucose-dependent manner using such transfected cells. Also provided are methods of treating a subject having Type II diabetes, methods of treating a subject prone to hyperglycemia or suffering from hyperglycemia and methods of reducing weight in a subject. |
priorityDate |
2007-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |